恶性肿瘤并发皮肤瘙痒症5例临床分析

作者认为恶性肿瘤引起的瘙痒有二种特点:(1)患者难以忍受;(2)抗组织胺药物无效。     

妊娠期肝内胆汁淤积症51例临床分析

目的 了解妊娠期肝内胆汁淤积症的临床表现、妊娠结局.方法 对住院治疗的妊娠期肝内胆汁淤积症51例,回顾分析临床表现、治疗及结局.结果 38例有皮肤瘙痒表现,占74.5%.49例(96.1%)血清总胆汁酸升高.经过治疗,49例(96.1%)至37周剖宫分娩.新生儿窒息2例(3.9%).结论 妊娠期肝内胆汁淤积症对母儿危害较大,但通过积极有效的治疗,预后良好.     

柔润保湿霜联合咪唑斯汀、润燥止痒胶囊治疗老年瘙痒症的效果观察*

目的：观察柔润保湿霜联合咪唑斯汀、润燥止痒胶囊治疗老年瘙痒症的临床疗效和安全性。方法：将入选的135例老年瘙痒症患者随机分为3组,各45例,观察组外用柔润保湿霜,bid,口服咪唑斯汀10 mg/d和润燥止痒胶囊4粒/次,3次/d;对照1组口服咪唑斯汀10 mg/d和润燥止痒胶囊4粒/次,tid;对照2组仅外用柔润保湿霜,bid;治疗4周后判定疗效。结果：观察组治愈率为44.44%,有效率为75.56%;对照1组的治愈率为28.89%,有效率为66.67%;对照2组的治愈率为22.22%,有效率为51.11%;观察组有效率和痊愈率均明显高于对照组(均P＜0.05)。皮肤瘙痒临床症状体征评分结果显示,观察组比两对照组显著降低(P＜0.05)。3组均未出现明显不良反应而导致治疗方案终止。结论：外用柔润保湿霜联合口服咪唑斯汀、润燥止痒胶囊可显著改善老年瘙痒症患者的病情。     

银屑病瘙痒发病机制的研究现况

瘙痒是多数原发性皮肤疾病及某些系统性疾病常见的临床症状。银屑病患者瘙痒发生率较高,但其具体发病机制复杂且尚不清楚。银屑病皮肤瘙痒的发生、发展源于神经、免疫、内分泌和血管系统等的共同参与。本文对银屑病瘙痒发病机制中涉及的相关介质进行综述,旨在提高对瘙痒症状的认识以及进一步研究缓解瘙痒的治疗方案。     

外阴接触性皮炎的发生及正确评估

女性外阴瘙痒是皮肤科及妇产科门诊的常见症状,外阴接触性皮炎是最常引起外阴瘙痒症状的原因之一。文中就外阴皮肤对于接触性刺激及过敏的敏感性,刺激性接触性皮炎(irritant contact dermatitis,ICD)及过敏性接触性皮炎(allergic contact dermatitis,ACD)的发病情况,外阴药物接触性皮炎及如何正确认识和评估外阴接触性皮炎等方面进行综述。     

HIV相关性瘙痒性丘疹的研究现状

人类免疫缺陷病毒(human immunodeficiency virus,HIV)相关性瘙痒性丘疹(pruritic papular eruption,PPE)是HIV感染者中常见的皮肤表现。HIV-PPE在热带地区发病率较高。临床表现以慢性、瘙痒性、对称性丘疹为特征。但HIV-PPE的病因及发病机制还不清楚,病理特征尚未明确。HIV-PPE与CD4细胞计数下降有一定相关性。目前缺乏有效的治疗方法。     

Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis

1. Download : Download high-res image (152KB)
2. Download : Download full-size image

     

Effectiveness and safety profiling of zolpidem and acupressure in CKD associated pruritus: An interventional study

Background:Chronic kidney disease (CKD)-associated pruritus (CKD-aP) contributes to poor quality of life, including reduced sleep quality and poor sleep quality is a source of patient stress and is linked to lower health-related quality of life. This study aimed to investigate the effectiveness of zolpidem 10 mg and acupressure therapy on foot acupoints to improve the sleep quality and overall quality of life among hemodialysis patients suffering from CKD-aP.Method:A multicenter, prospective, randomized, parallel-design, open label interventional study to estimate the effectiveness of zolpidem (10 mg) oral tablets versus acupressure on sleep quality and quality of life in patients with CKD-aP on hemodialysis. A total of 58 hemodialysis patients having sleep disturbance due to CKD-aP completed the entire 8-week follow-up. The patients were divided into a control (acupressure) group of 28 patients and an intervention (zolpidem) group of 30 patients.Results:A total of 58 patients having CKD-aP and sleep disturbance were recruited. In the control group there was a reduction in the PSQI score with a mean ± SD from 12.28 ± 3.59 to 9.25 ± 3.99, while in the intervention group the reduction in PSQI score with a mean ± SD was from 14.73 ± 4.14 to 10.03 ± 4.04 from baseline to endpoint. However, the EQ5D index score and EQ-visual analogue scale (VAS) at baseline for the control group with a mean ± SD was 0.49 ± 0.30 and 50.17 ± 8.65, respectively, while for the intervention group the values were 0.62 ± 0.26 and 47.17 ± 5.82, respectively. The mean EQ5D index score in the control group improved from 0.49 ± 0.30 to 0.53 ± 0.30, but in the intervention group there was no statistical improvement in mean EQ5D index score from 0.62 ± 0.26 to 0.62 ± 0.27 from baseline to week 8. The EQ 5D improved in both groups and the EQ-VAS score was 2.67 points higher at week 8 as compared to baseline in the control group, while in the intervention group the score was 3.33 points higher at week 8 as compared to baseline. Comparing with baseline, the PSQI scores were significantly reduced after week 4 and week 8 (P =  < .001). Furthermore, at the end of the study, the PSQI scores were significantly higher in the control as compared to the intervention group (P = .012).Conclusion:An improvement in sleep quality and quality of life among CKD-aP patients on hemodialysis has been observed in both the control and intervention groups. Zolpidem and acupressure safety profiling showed no severe adverse effect other that drowsiness, nausea and daytime sleeping already reported in literature of zolpidem.